Pharmacology
Conference Coverage
New ‘twincretin’ pemvidutide: Another option for obesity
“We need to look at the person holistically and at other aspects of cardiometabolic health and treat in a personalized way and choose treatments...
Conference Coverage
Metabolic effects of estetrol are promising in postmenopausal women
Preliminary findings suggest estetrol continues to hold potential for becoming an additional option in treating menopause symptoms.
Conference Coverage
Trials say start sacubitril-valsartan in hospital in HF with ‘below normal’ LVEF
The risk-reduction benefit reached 41% among the overwhelming majority of patients with a left ventricular ejection fraction.
Latest News
Roflumilast side effect benefits patients with psoriasis and overweight/obesity
An “extraordinary” finding was how some patients’ weight status based on their BMI changed throughout the study.
News
Novel triple-threat approach to acne beats placebo
Patients in the IDP-126 groups for both studies 1 and 2 had significantly greater absolute mean reductions in both inflammatory and...
News
FDA approves new drug for ulcerative colitis
The approval of etrasimod was based on safety and efficacy data from two randomized, double-blind, placebo-controlled phase 3 trials.
Conference Coverage
Ocrelizumab benefit confirmed in older patients with MS
Lower rates of relapse were seen in older patients taking ocrelizumab, but the risk for relapse in this age group is low.
News
GLP-1 agonists linked to higher risk for rare but serious GI complications
Investigators say their findings are not about scaring people off the weight-loss drugs, but instead about increasing awareness that these...
Conference Coverage
Confirmed: Intermittent use of benzodiazepines is the safest option
“We’ve always known that there was a problem, but there haven’t been high-quality epidemiological studies like this that allowed us to say what...
Conference Coverage
Esketamine bests quetiapine for severe depression in head-to-head trial
“These patients are not resistant, they just have resistance to monoaminergic drugs.”